title: Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine.
abstract: The efficacy of moclobemide (300-450 mg/day) was compared with fluoxetine (20-40 mg/day) in a double-blind, multicentre study in 209 patients with new episodes of depression selected from 612 consecutive depressed patients representative of those consulting psychiatric services in Finland. Antidepressant efficacy was assessed with the Hamilton Depression Rating Scale (HDRS), Montgomery-Asberg Depression Rating Scale and Clinical Global Impression (CGI). The Medical Outcome Study Short-form General Health Survey (SF-20) and 15D Measure of Quality of Life were used to measure effectiveness in terms of health-related quality of life. Efficacy was evident with both drug treatments, with 67% in the moclobemide group and 57% in the fluoxetine group having a reduction in HDRS of more than 50%. Similarly, 77% of the patients in the moclobemide group and 67% in the fluoxetine group were assessed on the CGI as much better or very much better after 6 weeks of treatment. The most commonly reported adverse events were nausea, other gastrointestinal symptoms, nervousness, dizziness and sleep disorders. Nausea was significantly more common in the fluoxetine group and was found especially in women. Premature terminations of treatment were 18% in the moclobemide and 21% in the fluoxetine group. A significant change for the better in quality of life was found in both treatment groups, even at week 2 but especially after 6 weeks of treatment. Improvement was not only seen in dimensions measuring depression or mental health but also in other dimensions.
authors.affiliation: Department of Mental Health, National Public Health Institute, Helsinki, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Lonnqvist
authors.forename: H
authors.initials: H
authors.lastname: Sintonen
authors.forename: E
authors.initials: E
authors.lastname: Syvälahti
authors.forename: B
authors.initials: B
authors.lastname: Appelberg
authors.forename: T
authors.initials: T
authors.lastname: Koskinen
authors.forename: T
authors.initials: T
authors.lastname: Mannikko
authors.forename: O P
authors.initials: OP
authors.lastname: Mehtonen
authors.forename: M
authors.initials: M
authors.lastname: Naarala
authors.forename: S
authors.initials: S
authors.lastname: Sihvo
authors.forename: J
authors.initials: J
authors.lastname: Auvinen
mesh_terms: D000328:Adult; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology*; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life
chemical_list: D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D005473:Fluoxetine; D020912:Moclobemide